- Home
- RDIB vs SLGL Comparison
RDIB vs SLGL Comparison
Compare RDIB & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDIB | SLGL |
|---|---|---|
| Founded | 1937 | 1997 |
| Country | United States | Israel |
| Employees | 2005 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.7M | 240.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RDIB | SLGL |
|---|---|---|
| Price | $9.01 | $85.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | 4.1K | ★ 17.8K |
| Earning Date | 05-14-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $4.04 | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.10 | $8.06 |
| 52 Week High | $17.40 | $97.97 |
Technical Indicators
Market Signals| Indicator | RDIB | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 66.56 |
| Support Level | $8.83 | $70.05 |
| Resistance Level | $10.72 | $85.33 |
| Average True Range (ATR) | 0.43 | 4.56 |
| MACD | 0.00 | 0.81 |
| Stochastic Oscillator | 39.74 | 87.98 |
Price Performance
Historical ComparisonAbout RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.